NCT06128720 Hyperbaric Oxygen Therapy for Optic Neuropathies
| NCT ID | NCT06128720 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Optic Neuropathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2022-11-01 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2022-11-01 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to evaluate the neuroprotective efficacy of hyperbaric oxygen for the treatment in patients with optic neuropathy.
Eligibility Criteria
Inclusion Criteria: * Patients must meet all of the following criteria to join the study (all eligibility criteria must be met at the screening and baseline visits unless otherwise noted): * Participant must be at least 18. * Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE). * Participant's with clinical evidence of optic neuropathy. * Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety. Exclusion Criteria: * Participant is unable to comply with study procedures or follow-up visits. * Participant has evidence of corneal opacification or lack of optical clarity. * Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a drug by ocular (if in the study eye) or systemic administration. * Participant is pregnant or lactating. * Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments. * Children and comatose patients. * Participant abusing drugs or alcohol. * Prior treatment with hyperbaric oxygen within the last 6 months. * Participant with claustrophobia or that cannot decompress properly.
Contact & Investigator
Jeffrey L Goldberg, MD PhD
STUDY CHAIR
Stanford University
Frequently Asked Questions
Who can join the NCT06128720 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Optic Neuropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06128720 currently recruiting?
Yes, NCT06128720 is actively recruiting participants. Contact the research team at zacwenn@stanford.edu for enrollment information.
Where is the NCT06128720 trial being conducted?
This trial is being conducted at Palo Alto, United States.
Who is sponsoring the NCT06128720 clinical trial?
NCT06128720 is sponsored by Stanford University. The principal investigator is Jeffrey L Goldberg, MD PhD at Stanford University. The trial plans to enroll 60 participants.